Payment overview · 2025
General Payments
$313.12
7 reported records · 6 companies
Healthcare provider profile · identity verified
Edwin Chan, MD
Allopathic & Osteopathic Physicians|Family Medicine · PALM BAY, FL · NPI 1124142054
Verified facts
What the public records show
CMS Open Payments records show Edwin Chan, MD received $313.12 in general payments during 2025 across 7 reported records.
Phathom Pharmaceuticals, Inc. accounted for 57.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $178.35 | 57.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.19 | 12.5% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $33.78 | 10.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.24 | 8.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.34 | 6.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.22 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $313.12 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $178.35 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $33.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 505 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 431 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 367 | 127 |
| Lisinopril | Lisinopril | 357 | 108 |
| Losartan Potassium | Losartan Potassium | 315 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 276 | 101 |
| Escitalopram Oxalate | Escitalopram Oxalate | 206 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 56 |
| Metformin Hcl Er | Metformin Hcl | 175 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 168 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 58 |
| Gabapentin | Gabapentin | 157 | 48 |
| Omeprazole | Omeprazole | 155 | 52 |
| Meloxicam | Meloxicam | 150 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 56 |
| Simvastatin | Simvastatin | 130 | 37 |
| Ozempic | Semaglutide | 129 | 32 |
| Furosemide | Furosemide | 128 | 35 |
| Alprazolam | Alprazolam | 121 | 34 |
| Azithromycin | Azithromycin | 117 | 101 |
| Metformin Hcl | Metformin Hcl | 117 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 107 | 40 |
| Telmisartan | Telmisartan | 102 | 26 |
| Montelukast Sodium | Montelukast Sodium | 97 | 33 |
| Trazodone Hcl | Trazodone Hcl | 97 | 35 |
| Potassium Chloride | Potassium Chloride | 95 | 31 |
| Eliquis | Apixaban | 94 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 18 |
| Donepezil Hcl | Donepezil Hcl | 91 | 17 |
| Sertraline Hcl | Sertraline Hcl | 90 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 28 |
| Tramadol Hcl | Tramadol Hcl | 76 | 26 |
| Allopurinol | Allopurinol | 73 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 26 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 68 | 24 |
| Famotidine | Famotidine | 67 | 24 |
| Methylprednisolone | Methylprednisolone | 65 | 56 |
| Mounjaro | Tirzepatide | 65 | 12 |
| Ezetimibe | Ezetimibe | 64 | 20 |
| Jardiance | Empagliflozin | 64 | 15 |
| Mirtazapine | Mirtazapine | 59 | 17 |
| Glimepiride | Glimepiride | 56 | 17 |
| Terazosin Hcl | Terazosin Hcl | 56 | 13 |
| Finasteride | Finasteride | 55 | 15 |
| Carvedilol | Carvedilol | 54 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Lovastatin | Lovastatin | 51 | 13 |
| Alendronate Sodium | Alendronate Sodium | 48 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 17 |
| Pregabalin | Pregabalin | 43 | 17 |
| Valsartan | Valsartan | 43 | 13 |
| Memantine Hcl Er | Memantine Hcl | 42 | suppressed |
| Spironolactone | Spironolactone | 40 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 11 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 13 |
| Fenofibrate | Fenofibrate | 36 | 11 |
| Methocarbamol | Methocarbamol | 36 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 28 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | 15 |
| Atenolol | Atenolol | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | 11 |
| Clonazepam | Clonazepam | 27 | 12 |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Linzess | Linaclotide | 22 | 12 |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Prolia | Denosumab | 17 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 13 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Naloxone Hcl | Naloxone Hcl | 13 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $313.12 · 7 records | Phathom Pharmaceuticals, Inc. | Cologuard Collection Kit, FARXIGA, NURTEC ODT, QULIPTA, UBRELVY, VOQUEZNA, WATCHMAN FLX, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error